Professor Mahendra Patel OBE, CEO of the Oxford University Centre for Research Equity (CfRE), has been appointed as an independent expert member of the UK
Pharmacy Professional Leadership Advisory Board.
The newly established Board comprises nine independent expert members (IEMs) with outstanding leadership capabilities, who were appointed through open recruitment,
ensuring a "broad, balanced, and diverse" representation.
Sir Hugh Taylor KCB, the Independent Chair of the Board, and the UK Chief Pharmaceutical Officers (CPhOs) - Andrew Evans (Wales), Cathy Harrison (Northern Ireland),
Alison Strath (Scotland), and David Webb (England) - announced the appointment of IEMs in an open letter to the UK pharmacy professions.
"Bringing a wealth of experience and expertise, they will play a pivotal role in the Board's work to deliver an exciting vision through supporting a new and dynamic
phase of collaboration," the CPhOs said.
As the CEO of CfRE, Professor Patel spearheads efforts aimed at addressing inequalities in healthcare.
"I dread the day, the accountant turns to me and says 'this isn't working' - as an owner, we shelter our patients and teams from the financial pressures
we feel on a daily basis," shares S.G Barai Pharmacy owner, Reena Barai.
Today, S.G Barai Pharmacy in Sutton, Surrey joined pharmacies nationwide in the #SaveOurPharmacies day of action, organised by the National Pharmacy Association
(NPA) to spotlight the critical funding crisis facing community pharmacies across the UK.
Recent figures reveal that over the past decade, more than 1,400 pharmacies have closed in England, Wales, and Northern Ireland, with additional closures looming
in Scotland due to financial pressures.
The NPA reports that three-quarters of pharmacies are operating at a loss, exacerbated by real-terms cuts to funding.
"We turned our lights off and wore black today to symbolize the precarious situation pharmacies like ours are facing," said Reena Barai who owns the pharmacy.
The World Health Organization (WHO) issued a warning on Thursday regarding falsified semaglutide medications used for treating type 2 diabetes and obesity
in select countries.
This WHO Medical Product Alert addresses three falsified batches of the specific brand Ozempic that were detected in Brazil (October 2023), the United Kingdom
and Northern Ireland (October 2023), and the United States (December 2023). These falsified semaglutide products were distributed through the regulated supply chain.
Novo Nordisk, the genuine manufacturer of Ozempic, confirmed that the three products mentioned in the alert are falsified and were not produced by the company.
Healthcare professionals, regulatory authorities and the public are advised to remain vigilant regarding these falsified batches of medicines.
Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, urged stakeholders to stop any usage of suspicious medicines and
report them to relevant authorities.
A community pharmacist was applauded for his 'quick-thinking' action in treating a Co Down woman with a fatal bee sting.
Joan Johnson, from Moira, was stung on her scalp in her home garden. After the bite, she noticed allergic reactions on her neck and ears with severe itching
and redness.
However, she was advised to visit her local pharmacy by the GP where the pharmacist, Stephen Joyce, quickly administered life-saving antihistamine and an
adrenaline injection while an ambulance was called.
Joan hailed the 'treatment' and the 'professionalism' of the whole team for saving her life.
"What was just a simple bee-sting, quickly became something very serious. On arrival at the pharmacy on the advice from my GP, I was dealt with very promptly
and Stephen was summoned and immediately took control of the situation.
"I was given an urgent antihistamine, but quickly started feeling lightheaded and faint. The pharmacy team assisted me to a chair and called an
ambulance," she said.
Laganside Crown Court, on Friday, sentenced Gerard Cullinan, a 48-year-old pharmacist and Director of Castlereagh Pharmacy Ltd in East Belfast, for
unlawfully supplying controlled prescription medicines, including co-codamol and fentanyl, and for failing to maintain controlled drugs registers.
Cullinan was sentenced to 11 months imprisonment, suspended for three years, and his pharmacy was fined £8,000.
The sentencing follows an investigation by the Department of Health's Medicines Regulatory Group (MRG), which uncovered that Cullinan's pharmacy on Castlereagh
Road had illegally supplied over 300,000 co-codamol tablets between January 2017 and June 2020.
Additionally, the MRG investigation identified significant breaches in record-keeping for Class A controlled drugs such as fentanyl, tapentadol, methylphenidate,
morphine, and oxycodone.
"It is a serious criminal offence to sell or supply prescription only medicines without a prescription," said Peter Moore, Senior Medicines Enforcement Officer at
the MRG, who led the investigation.
